Displaying One Session

Educational session

How does real-world evidence inform decision making for new drug funding?

Session Track
Public policy
Chairs
  • Christopher M. Booth (Kingston, Ontario, Canada)
Release Date
Thu, 16.09.2021

Introduction (ID 4632)

Speakers
  • Christopher M. Booth (Kingston, Ontario, Canada)
Duration
5 Minutes

The limitations of clinical evidence from trials when data presented for HTA: Immature survival data, selected patient populations, phase II data for uncommon cancers etc... (ID 4633)

Speakers
  • Nathan I. Cherny (Jerusalem, Israel)
Duration
15 Minutes

Real-world evidence and regulatory drug approval (ID 4634)

Speakers
  • Christopher M. Booth (Kingston, Ontario, Canada)
Duration
15 Minutes

RWE: When should it be used by EMA? (ID 4635)

Speakers
  • Francesco Pignatti (Amsterdam, Netherlands)
Duration
15 Minutes

Challenges of collecting RWE: Limitations of administrative data sets, complex methodological issues, responsibility for collecting data (ID 4636)

Speakers
  • Valery Lemmens (Eindhoven, Netherlands)
Duration
15 Minutes